CA-008
Phase 2Small molecule
CA-008 is one of 43 small molecule programs targeting Ventral Hernia. It is currently in Phase 2.
3
Indications
7
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
275 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1Cymbalta
Alnylam PharmaceuticalsPreclinical
CA-008
CConcentric Analgesics
Phase 2
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Xarelto
WWim Janssens
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Sufenta
LLeaf Vertical Inc.
Preclinical
EXPAREL
Pacira Pharmaceuticals, IncPreclinical
Nucynta
CCollegium Pharmaceutical, Inc.
Preclinical
Zanaflex
LLegacy Health System
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bunion2 trials
Hallux valgus1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CA-008. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CConcentric Analgesics